Pharmacogenetics of Response to Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Prospective Study [0.03%]
绝经后骨质疏松症对双膦酸盐治疗反应的药物遗传学：前瞻性研究
Sirin Akbulut Ayturk,Ozden Ozyemisci Taskiran,Ebru Koseoglu Tohma et al.
Sirin Akbulut Ayturk et al.
Background: This study aims to investigate the effect of genetic polymorphisms of vitamin D receptor (VDR), estrogen receptor 1 (ER1), and Col1a1 on the response to bisphosphonate (BP) therapy in women with postmenopausal...
Transforming Growth Factor-β Signaling Inhibits the Osteogenic Differentiation of Mesenchymal Stem Cells via Activation of Wnt/β-Catenin Pathway [0.03%]
转化生长因子-β信号通过激活Wnt/β-连环蛋白通路抑制间充质干细胞的成骨分化
Mahsa Tahoori,Azita Parvaneh Tafreshi,Fatemeh Naghshnejad et al.
Mahsa Tahoori et al.
Background: Due to the contradictory and temporally variable effects of transforming growth factor-β (TGF-β) and the Wnt/β-catenin pathways on osteogenic differentiation in different stem cell types, we sought to exami...
Arzu Jalilova,Alessandra Cocca
Arzu Jalilova
This review aims to synthesize current knowledge regarding the use of bisphosphonates (BPs) in the treatment of bone complications in patients with neurofibromatosis type 1 (NF1). NF1 is a genetic disorder marked by multiple benign tumors o...
Platelet Count Normalization Following Romosozumab Treatment for Osteoporosis in Patient with Immune Thrombocytopenic Purpura: A Case Report and Literature Review [0.03%]
免疫性血小板减少症患者抗骨质疏松药物罗莫佐单抗治疗后血小板计数正常化的1例报告及文献复习
Kyunghun Sung,Jeonghoon Ha
Kyunghun Sung
Romosozumab, which is approved for the treatment of osteoporosis, has a dual-action mechanism that promotes bone formation and inhibits bone resorption. However, its association with an increased risk of major adverse cardiovascular events,...
Relationships among Physical Activity Bone Mineral Density and Body Composition in Obese and Athletes [0.03%]
肥胖者和运动员的体力活动、骨密度及身体成分的关系分析
Dutsadee Suttho,Sudarat Apibantaweesakul,Jatesupa Soponputthaporn et al.
Dutsadee Suttho et al.
Background: Osteoporosis is a significant global public health issue, increasingly affecting younger individuals and placing substantial economic burdens on society. Risk factors vary, with non-modifiable ones like age an...
Physical Performance Level and Patient-Reported Outcomes in Female Patients with Distal Radius Fracture [0.03%]
远端桡骨骨折女性患者的体能水平和患者报告结果测量指标分析
Byung Hun Oh,Rawdhah Kamil Kalantan,Jae Kwang Kim et al.
Byung Hun Oh et al.
Background: This study aimed to evaluate the influence of physical performance level on patient-reported outcomes after surgery for distal radius fractures (DRF). ...
Discriminatory Accuracy of Fracture Risk Assessment Tool in Asian Populations: A Systematic Review and Meta-Analysis [0.03%]
亚洲人群骨折风险预测工具准确性的系统评价和 meta 分析
Dheeraj Jha,Manju Chandran,Namki Hong et al.
Dheeraj Jha et al.
Background: This review explores the discriminative ability of fracture risk assessment tool (FRAX) in major osteoporotic fracture (MOF) and hip fracture (HF) risk prediction and the densitometric diagnosis of osteoporosi...
Age- and Sex-Related Volumetric Density Differences in Trabecular and Cortical Bone of the Proximal Femur in Healthy Population [0.03%]
健康人群股骨近端骨小梁和皮质骨体积密度的年龄和性别相关差异
María Lorena Brance,Fernando Daniel Saraví,Muriel M Henríquez et al.
María Lorena Brance et al.
Background: There are age- and sex-related increases in the prevalence of osteoporosis. Bone densitometry based on dual energy X-ray absorptiometry (DXA) is the gold standard for the assessment of bone mineral density (BM...
Praopilad Srisuwarn,Richard Eastell,Syazrah Salam
Praopilad Srisuwarn
Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification, a...
Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary Hospital [0.03%]
印尼三级医院骨生成不全症的唑来磷酸治疗展望
Tri Wahyu Martanto,Aliefio Japamadisaw,Dian Nurhayati et al.
Tri Wahyu Martanto et al.
Background: Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research on clinic...